Header Logo

Connection

KEVIN GAREY to Vancomycin

Back to Details
This is a "connection" page, showing publications KEVIN GAREY has written about Vancomycin.
KEVIN GAREY
Connection Strength
5.727
Vancomycin
  1. Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. Antimicrob Agents Chemother. 2025 Feb 13; 69(2):e0125124.
    View in: PubMed
    Score: 0.834
  2. A Vancomycin HPLC Assay for Use in Gut Microbiome Research. Microbiol Spectr. 2022 06 29; 10(3):e0168821.
    View in: PubMed
    Score: 0.692
  3. Perils, Pitfalls, and Promise of Primary Prophylaxis for Clostridioides difficile Infection. Clin Infect Dis. 2020 08 22; 71(5):1140-1141.
    View in: PubMed
    Score: 0.615
  4. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect. 2013 Sep; 85(1):28-32.
    View in: PubMed
    Score: 0.375
  5. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy. 2012 Feb; 32(2):129-34.
    View in: PubMed
    Score: 0.339
  6. Economic benefit of appropriate timing of vancomycin prophylaxis in patients undergoing cardiovascular surgery. Pharmacotherapy. 2008 Jun; 28(6):699-706.
    View in: PubMed
    Score: 0.264
  7. Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. Antimicrob Agents Chemother. 2008 Feb; 52(2):446-51.
    View in: PubMed
    Score: 0.254
  8. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther. 2006 Aug; 28(8):1208-1216.
    View in: PubMed
    Score: 0.232
  9. Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother. 2006 Sep; 58(3):645-50.
    View in: PubMed
    Score: 0.231
  10. Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization. Ann Pharmacother. 2006 Mar; 40(3):381-5.
    View in: PubMed
    Score: 0.225
  11. Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response. Clin Infect Dis. 2024 07 19; 79(1):15-21.
    View in: PubMed
    Score: 0.202
  12. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 06 14; 78(6):1462-1472.
    View in: PubMed
    Score: 0.200
  13. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile. Antimicrob Agents Chemother. 2024 03 06; 68(3):e0162123.
    View in: PubMed
    Score: 0.196
  14. Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers. J Infect Dis. 2024 01 12; 229(1):273-281.
    View in: PubMed
    Score: 0.194
  15. Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection. Antimicrob Agents Chemother. 2022 08 16; 66(8):e0224421.
    View in: PubMed
    Score: 0.175
  16. Fulminant Clostridioides difficile Infection: A Review of Treatment Options for a Life-Threatening Infection. Semin Respir Crit Care Med. 2022 02; 43(1):28-38.
    View in: PubMed
    Score: 0.170
  17. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob. 2016 Apr 12; 15:22.
    View in: PubMed
    Score: 0.114
  18. Real-world performance of a microarray-based rapid diagnostic for Gram-positive bloodstream infections and potential utility for antimicrobial stewardship. Diagn Microbiol Infect Dis. 2015 Jan; 81(1):4-8.
    View in: PubMed
    Score: 0.102
  19. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS One. 2014; 9(7):e102848.
    View in: PubMed
    Score: 0.101
  20. Inhibition of biofilm formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother. 2012 Aug; 56(8):4360-4.
    View in: PubMed
    Score: 0.087
  21. Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates. J Antimicrob Chemother. 2020 04 01; 75(4):859-867.
    View in: PubMed
    Score: 0.037
  22. A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment. J Vis Exp. 2017 05 25; (123).
    View in: PubMed
    Score: 0.031
  23. Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. Antimicrob Agents Chemother. 2016 06; 60(6):3519-23.
    View in: PubMed
    Score: 0.029
  24. A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile. Anaerobe. 2016 Aug; 40:10-4.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.